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Abstract
Background: Asthma is a disease encompassing a variety of contributing factors. Phenotyping of asthma based on
the profile of accumulated granulocytes in the airways has been performed to explore the mediators involved in
allergic bronchial inflammation. The aim of this study was to clarify the characteristics of the CXC chemokine
superfamily induced by IFN-γ, namely CXCR3 ligands, in the airways of patients with asthma stratified by the
differential proportion of granulocytes in sputum.
Methods: Sputum was induced in 39 adult patients with asthma and 12 healthy subjects. Sputum samples were
analyzed for total cell counts and differentials, and concentrations of IFN-γ–inducible protein 10 kDa (IP-10, CXCL10),
monokine induced by IFN-γ (Mig, CXCL9), IFN-inducible T cell a chemoattractant (I-TAC, CXCL11), and IL-8 in the
supernatants were assayed by ELISA.
Results: Sputum concentrations of IP-10, Mig, and IL-8 were significantly higher in asthma than in healthy subjects.
IP-10, Mig, and IL-8 were significantly higher in the mixed granulocyte subtype (eosinophils ≥ 2 % and
neutrophils ≥ 40 % in sputum) than in healthy subjects. Additionally, IP-1 0 was significantly higher in the mixed
granulocyte subtype than in eosinophil-predominant or neutrophil-predominant subtype (eosinophil percentage ≥
2 % or neutrophil percentage ≥ 40 %). Mig and IL-8 were significantly higher in the mixed granulocyte subtype
than in the paucigranulocyte subtype (eosinophils < 2 % and neutrophils < 40 % in sputum). I-TAC was not different
between healthy subjects and asthmatics or granulocyte subtypes. All CXCR3 ligands were significantly associated
with the composite of the eosinophil and neutrophil ratio in patients with asthma. Only Mig was significantly
correlated with the total eosinophil and neutrophil ratio in patients with asthma on adjusted partial correlation
analysis. Mig and IL-8 were significantly negatively correlated with forced expiratory volume in 1 s % predicted
(% FEV1) in patients with asthma.
Conclusions: CXCR3 ligands may serve as potent promoters in eosinophilic and neutrophilic airway inflammation
in asthma.
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granulocytic inflammation
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Background
Asthma is a heterogeneous disease caused by genetic
and environmental factors. The diversity of bronchial in-
flammation in asthma leads to difficulty treating severe
asthma. To develop a better understanding of severe
asthma, genotype, endotype, and phenotype cluster ana-
lyses of asthma have been used [1–8]. Recently, asthma
endotype cluster analysis followed by genotype or
phenotype cluster analysis has achieved successful clin-
ical results, including anti-IL-5 antibody therapy for
persistent eosinophilic severe asthma and anti- IL-4 or
anti-IL-13 antibody therapy for high-Th2-type severe
asthma [9–12]. These results imply that endotype cluster
analysis is an important approach for determining the
treatment of asthma.
There has been increasing evidence from endotype
cluster analysis of asthma based on the kind of granulo-
cyte that is predominant in the airway. Assessment on
the basis of either the eosinophil or the neutrophil ratio
has been performed [13–19]. In greater detail, cases are
divided into 4 clusters for endotype cluster analysis of
asthma, including the paucigranulocytic inflammatory
subtype, the eosinophil-predominant inflammatory sub-
type, the neutrophil-predominant inflammatory subtype,
and the mixed granulocyte inflammatory subtype [20].
Two Severe Asthma Research Program (SARP) studies
reported that moderate-to-severe asthma was character-
ized by neutrophil-predominant or mixed granulocytic
inflammation [21, 22]. Adult-onset severe asthma has
higher sputum eosinophil and blood neutrophil counts
than mild-to-moderate persistent asthma [23]. The strati-
fication of asthma based on the predominant granulocyte
in sputum has also shown elevation of some cytokines or
chemokines [21–28].
IFN-γ–inducible protein 10 kDa (IP-10, CXCL10),
monokine induced by IFN-γ (Mig, CXCL9), and IFN-
inducible T cell a chemoattractant (I-TAC, CXCL11) be-
long to the CXC chemokine subfamily that binds to
CXCR3 [29, 30]. CXCR3 ligands have been considered
to be involved in the Th1-type immune response be-
cause they are produced by various cells in response to
IFN-γ [29, 30]. In general, CXCR3 ligands accumulate
mainly in lymphocytes and subsequent neutrophils. The
expression of CXCR3 ligands has been shown to be up-
regulated in delayed-type immune responses of the skin,
in murine macrophages infected with Mycobacterium tu-
berculosis [31], atherosclerosis [32], viral meningitis [33],
and viral-activated neutrophils [34]. Mig has been shown
to be increased in bronchoalveolor lavage (BAL) fluids
obtained from patients with acute respiratory distress
syndrome in cooperation with CXC3 receptor expression
on neutrophils in BAL fluid [34].
Recently, IP-10 has been reported to be involved in al-
lergic bronchial inflammation. For example, IP-10 in
BAL increased to biologically relevant levels in patients
with asthma after segmental allergen challenge [35].
Serum IP-10 concentration was specifically increased in
rhinovirus-induced asthma exacerbation [36]. However,
the available information in terms of the contribution of
IP-10 to asthma exacerbation remains insufficient to de-
termine whether IP-10 and other CXCR3 ligands are
also implicated in allergic bronchial inflammation in
stable asthma. Moreover, whether trends in CXCR3 li-
gands depend on the severity of asthma or on granulo-
cytic inflammatory subtype in asthma has never been
fully studied.
We hypothesized that CXCR3 ligands would be ele-
vated in stable asthma and would characterize granulo-
cytic inflammatory subtypes in asthma. To clarify this,
the concentrations of CXCR3 ligands and IL-8 were
measured in sputum obtained from patients with asthma
and healthy volunteers. The differences in these chemo-
kines between the grades of asthma severity according
to the European Respiratory Society (ERS)/American
Thoracic Society (ATS) statement and their associations
with respiratory functions were investigated [37]. Finally,
the levels of CXCR3 ligands were compared among
granulocytic inflammatory asthma subtypes, especially
mixed granulocyte inflammatory subtype.
Methods
Patients
Patients with asthma and normal control subjects were
recruited from the Allergy Center of the Saitama Med-
ical University Hospital. Asthma was defined according
to the GINA guidelines [38], including a clear clinical
history of current symptoms and either an increase in
baseline forced expiratory volume in 1 s (FEV1) of ≥12 %
over baseline values after inhalation of 200 μg of salbuta-
mol aerosol, or the presence of bronchial hyperrespon-
siveness defined by methacholine PC20 of < 4 mg/mL.
Exclusion criteria were: (1) lung disease other than
asthma considered to interfere with the evaluation; (2)
admission to an emergency room/intensive care unit be-
cause of asthma during the previous 1 month; (3) 3 or
more courses of oral corticosteroids or hospitalization
for asthma during the previous 1 month; (4) respiratory
infections during the previous 1 month; (5) history of
being treated with immunosuppressants; (6) pregnant;
and (7) comorbid systemic diseases, including cancer, se-
vere renal failure, or severe heart failure; and (8) current
smoker. Healthy subjects were recruited from the hos-
pital staff and had no history of asthma or other respira-
tory disease and FEV1 > 80 % predicted. All subjects
performed pulmonary function tests, and forced vital
capacity (FVC) and FEV1 were measured according to
the ATS guidelines [39] using an AS307 spirometer
(Minato Medical Science, Osaka, Japan). The fraction of
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exhaled nitric oxide (FeNO) was also measured for all
subjects using a chemiluminescence analyzer (SiEVER
280i NIPPON MEGACARE Co, Ltd, Tokyo, Japan) with a
resolution of 1 part per billion (ppb) according to the
recommendations of the ATS. Severe asthma was defined
according to the International ERS/ATS guidelines pub-
lished in 2014 [37], in which severe asthma required treat-
ment with high-dose inhaled corticosteroid (ICS) and
second controllers, since guidelines suggested medications
for Global Initiative For Asthma (GINA) steps 4–5 asthma
for the previous year or systemic corticosteroid for ≥ 50 %
of the previous year to prevent it from becoming “uncon-
trolled” or which remains “uncontrolled” despite this ther-
apy. The study was approved by the Institutional Review
Board of the Saitama Medical University Hospital. Written
informed consent was obtained from all individuals.
Sputum induction and processing
Induced sputum was collected as described previously
[40–42]. Salbutamol was administered using a metered
dose inhaler. Fifteen minutes later, sterile hypertonic sa-
line (4.5 %) was inhaled using an ultrasonic nebulizer at
room temperature. Sputum was collected at 5-min inter-
vals for up to 30 min. Subjects were asked to rinse their
mouth with water before each expectoration to minimize
salivary contamination. All initial samples were dis-
carded. Induced sputum samples collected into 50-mL
polypropylene tubes were stored at 4 °C for further pro-
cessing. Hanks’ balanced salt solution (HBSS; 1 mL)
containing 1 % dithiothreitol (Sigma, St. Louis, MO,
USA) was added to sputum samples, and they were gen-
tly vortex-mixed and repeatedly aspirated at ambient
temperature until the mixture was homogeneous. Sam-
ples were diluted with HBSS to 5 mL, and separated by
centrifugation at 400 g for 10 min. Cytospin slides were
prepared by cytospin (Cytospin 3: Shandon, Tokyo,
Japan) and stained by May-Grunwald-Giemsa for differ-
ential cell counts. At least 500 inflammatory cells were
counted for each sample by an independent investigator.
Cytospin slides with squamous epithelial cells account-
ing for 50 % or less were deemed adequate for analysis.
Concentrations of IP-10, Mig, and I-TAC in sputum su-
pernatants were measured using a specific enzyme im-
munoassay (Cayman Chemicals; Ann Arbor, MI). The
lower limit of detection for these assays was 31.2 pg/mL
for IP-10, 62.5 pg/mL for Mig, and 7.81 pg/ml for I-TAC.
When any value was lower than the lower limit or not de-
tected, the lower limit of values were assigned to subjects.
Subject classification in accordance with sputum
eosinophil percent and neutrophil percent
Subjects were categorized into 3 subgroups based on the
percentages of eosinophils and neutrophils in their sputum;
the paucigranulocytic subtype (eosinophil percentage < 2 %
and neutrophil percentage < 40 %), the eosinophil-
predominant or neutrophil-predominant subtype (eosino-
phil percentage ≥ 2 % or neutrophil percentage ≥ 40 %), and
the mixed granulocyte subtype (eosinophil percentage ≥
2 % and neutrophil percentage ≥ 40 %). Various cut-off
points of sputum eosinophil (1 to 3 %) and neutrophil per-
centages (40 to 64 %) have been applied to the classification
of asthma inflammatory subtype [20–22, 25]. In the
SARP studies, eosinophil percentage ≥ 2 % and neutrophil
percentage ≥ 40 % in sputum were chosen for dividing the
subjects into the paucigranulocytic subtype, the eosinophil-
predominant subtype, the neutrophil-predominant subtype,
and the mixed granulocyte subtype [21, 22], because classi-
fying severe asthma patients at 61 % of sputum neutrophil
percentage, which corresponded to the 95th percentile of
sputum neutrophil percentages in healthy control subjects
and was adopted as a cut-off point for neutrophil percent-
age in an earlier study [20], allocated 75 % of the patients
with severe asthma to the non-neutrophilic asthma sub-
type. Similar to the SARP studies, this point was considered
too strict a distinction, since only 13 % (4/31) of all asthma
patients were placed in neutrophilic categories in our study.
Thus, 2 % for the eosinophil percentage and 40 % for the
neutrophil percentage were considered to be the appropri-
ate cut points for classifying the cases into 3 subgroups.
Statistical analysis
Values are expressed as means ± standard deviation (SD)
or medians with 25th–75th percentile ranges if not nor-
mally distributed. The Kolmogorov-Smirnov test or the
Leven test was performed to confirm a normal distribu-
tion. Parametric continuous variables in two groups
were tested by Student’s t-test. Nonparametric variables
in two groups were tested by the Mann–Whitney U test
and in more than two groups by the Kruskal-Wallis test.
Initial analyses with a significant difference were further
explored by post hoc pairwise analyses (Bonferroni correc-
tion). Associations between data were determined using
Pearson correlation coefficients. Categorical variables were
analyzed using χ2 tests. Values of P < 0.05 were considered
significant. Data were analyzed using SPSS version 20.0
(IBM, Armonk, New York, USA).
Results
Subjects’ demographics and characteristics
Forty eight patients with asthma and 19 normal control
subjects were enrolled. Appropriate sputum samples were
obtained from 39 asthmatic patients (80 %) and 12 normal
control subjects (63 %). Twenty eight patients (72 %) had
non-severe asthma, and 11 patients (28 %) had severe
asthma. The demographics and clinical characteristics of
the subjects in these groups are shown in Table 1 and
Table S1 (see Additional file 1). An additional data file
shows this in more detail. There were no significant
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differences in BMI and the number of patients with atopy
among the groups. Patients with asthma, particularly with
severe asthma were older than healthy subjects. The per-
centage of female and ex-smokers in patients with asthma
was significantly higher than in healthy subjects. The dur-
ation of disease of patients with severe asthma was signifi-
cantly longer than of non-severe asthma. Patients with
severe asthma were treated with significantly higher doses
of ICS than those with non-severe asthma. The percentage
of severe asthma treated with oral corticosteroids (OCS)
and leukotriene receptor antagonist was higher than non-
severe asthma. FEV1 and % FEV1 were significantly lower
in patients with non-severe and severe asthma than in
healthy subjects (p < 0.0001).
Sputum inflammatory cell pattern based on the
classification by asthma severity
Eosinophils ratio was higher in patients with asthma, es-
pecially with severe asthma than in healthy subjects
(Table 1). The total ratios of eosinophils and neutorphils
Table 1 Characteristics of Subjects
Asthma patients Healthy subjects P value*
Subjects, n (%) 39 12
Age, y 55 (20–72) 47 (30–57) 0.02
Male/female, n (Male, %) 16 (41)/23 4 (33)/9 0.05
BMI (kg/m2) 22.5 (3.8) 22.2 (3.1) N.S.
Duration of asthma (y) 6.5 (2–16.5) N. A. N. A.
Ex-smokers, n (%) 14 (36) 0 (0) 0.02
Medication
ICS dose (μg/day) 995 (400–1300) N. A. N. A.
Long acting β2-agonist, n (%) 27 (69) N. A. N. A.
Leukotriene receptor antagonist, n (%) 27 (69) N. A. N. A.
Oral corticosteroids, n (%) 8 (21) N. A. N. A.
Atopy, n (%) 25 (64) 5 (42) N.S.
Asthma control and health care use, past year
β-agonist use/day 0.00 (0.00–0.03) N. A. N. A.
Oral corticosteroid bursts 1.0 (0.0–2.0) N. A. N. A.
FEV1, L/min 2.0 (0.4) 3.2 (0.8) <0.0001
FEV1, % predicted 80.4 (20.3) 105.5 (14.6) <0.0001
FeNO, ppb 29.5 (14.0–45.5) N.D. N. A.
Cell population in sputum
% Squamous 16.7 (7.6–25.2) 32.9 (25.1–42.4) 0.03
% Macrophage 26.0 (19.0–43.1) 37.5 (27.6–4 3.2) N. S.
% Lymphocyte 7.3 (4.6–11.9) 7.5 (3.7–13.4) N. S.
% Neutrophil 29.9 (24.1–51.2) 21.6 (18.6–24.1) N. S.
% Eosinophil 6.4 (1.6–11.4) 0.5 (0.0–2.0) <0.0001
% Eosinophil 38.3 (29.8–63.1) 23.9 (18.6–24.8) 0.002
+ % Neutrophil
CXC chemokine in sputum
IP-10 (pg/mL) 60.1 (31.2–306.7) 31.2 (0.0) 0.01
Mig (pg/mL) 989.5 (62.5–2698.2) 62.5 (0.0) <0.0001
I-TAC (pg/mL) 7.8 (7.8–24.3) 7.8 (0.0) N. S.
IL-8 ( Log, pg/mL) 3120.3 (3.5, 1442.9 - 9115.1) 1356.6 (3.0, 522.6 - 2550.4) 0.01
Data are presented as means (SD) unless otherwise indicated. Nonparametric data are shown as medians (25 to 75 %). Age is shown as mean (minimum
to maximum)
ICS = inhalation corticosteroid (beclomethasone), where 1 μg beclomethasone = 1 μg budesonide = 0.5 μg fluticasone
*P values are calculated with the use of the Mann–Whitney U test for nonparametric data, Student’s t-test for variables with a parametric distribution, and Fisher’s
exact test for comparison of proportions
N. A.; not applicable. N.D.: not done
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in sputum were higher in patients with severe and non-
severe asthma than in healthy subjects (see Additional
file 2: Table S2). The prevalence of patients with severe
asthma was higher in the eosinophil-predominant sub-
type (33 %) and the mixed granulocytic subtype (25 %)
than in the paucigranulocytic subtype (20 %). There was
a significant negative correlation between the total eo-
sinophil ratio and neutrophil ratio in sputum and %
FEV1 in all subjects (r = −0.38, p = 0.009).
CXC chemokines in sputum based on the classification by
asthma severity
IP-10, Mig, and I-TAC were not detected in sputum of
any healthy subjects. In 17, 11 and 28 of patients with
asthma, IP-10, Mig and I-TAC were below the detection
limit in sputum, respectively. IP-10, Mig and IL-8 levels,
but not I-TAC levels, were higher in asthmatic patients
than in healthy subjects (Fig. 1). There was no difference
in any CXC chemokine between non-severe asthma and
severe asthma patients (Additional file 2: Table S2).
Subjects’ demographics and other characteristics based
on the classification by percentages of eosinophils and
neutrophils in sputum
The proportion of patients with severe asthma was high in
the mixed granulocytic subtype and in the eosinophil-
predominant subtype, similar to the result in the study
from the SARP group [22, 23]. Kaminska et al. showed
that the total eosinophil and neutrophil ratio in sputum
was associated with airway obstruction [43]. Additionally,
eosinophil and neutrophils were shown to express CXC3
receptors [44, 45]. Therefore, we decided to examine the
patterns of CXC chemokines according to the stratifica-
tion based on the percentages of eosinophils and neutro-
phils in the sputum.
The paucigranulocytic subtype (n = 9), the eosinophil or
neutrophil-predominant subtype (n = 22), and the mixed
granulocytic subtype (n = 8) were analyzed. The eosinophil
or neutrophil-predominant subtype was composed of
the eosinophil-predominant subtype (n = 19) and the
neutrophil-predominant subtype (n = 3). The demographics
and other characteristics of them are shown in Table 2.
There were no significant differences in age, sex, BMI and
number of patients with atopy among the 4 groups. There
were no significant differences in dose of ICS, daily OCS
use, adjunctive therapy and frequency of rescue β2-agonist
use or asthma exacerbation with OCS treatment in the past
year among the 3 granulocytic subtypes. The duration of
disease of patients with the mixed granulocytic subtype was
significantly longer than with the paucigranulocytic sub-
type. Patients in the eosinophil or neutrophil-predominant
subtype and the mixed granulocytic subtype had signifi-
cantly lower FEV1 and % FEV1 than healthy subjects.
There were no differences in pulmonary functions and
FeNO among the 3 granulocytic asthma subtypes.
CXC chemokines in sputum based on the sputum
inflammatory granulocytic pattern
To elucidate whether sputum CXC chemokines differed



































































Fig. 1 Sputum CXCR3 ligands and IL-8 in patients with asthma and healthy subjects. The comparison of sputum CXCR3 ligands and IL-8 between in
patients with asthma and healthy subjects is shown in a IP-10, b Mig, c I-TAC and d IL-8. Each closed dot represents a different subject. Boxes represent
the 25th and 75th percentiles, the central line represents the median, and solid circles represent outliers. Error bars indicate SDs. The comparison of
IP-10 and I-TAC between groups was analyzed using the Mann–Whitney U test. The comparison of Mig and IL-8 was analyzed using Student’s t-test
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chemokine data were evaluated according to the classifi-
cation by sputum inflammatory granulocytic pattern
(Fig. 2, Table 3). IP-10 was significantly higher only in
the mixed granulocytic subtype than in the eosinophil or
neutrophil-predominant subtype and in healthy subjects
(overall P = 0.002, Fig. 2a). Mig and IL-8 were signifi-
cantly higher in all 3 granulocytic subtypes than in
healthy subjects (overall P < 0.0001, 0.04, respectively,
Fig. 2b and d). Mig and IL-8 were also significantly
higher in the mixed granulocytic subtype than in the
paucigranulocytic subtype. I-TAC was not different
among the groups (Fig. 2c).
IP-10, Mig, I-TAC and IL-8 in sputum were signifi-
cantly correlated with the total sputum eosinophil and
neutrophil ratio in patients with asthma (Fig. 3a, b, c
and d). IP-10 in sputum had no relationships with the
ratios of either eosinophils or neutrophils in sputum in
patients with asthma. Mig, I-TAC and IL-8 in sputum
were significantly correlated with the sputum neutrophil
ratio, but not eosinophil in patients with asthma (neu-
trophil ratio v. s. Mig, R = 0.32, P = 0.05; I-TAC, R = 0.45,
P = 0.01; IL-8, R = 0.40, P = 0.02). IP-10 and Mig were
significantly correlated with IL-8 in patients with asthma
(IP-10, R = 0.42, P = 0.007; Mig, R = 0.64, P < 0.0001). The
partial correlation analysis adjusted with age, eosinophil
ratio and neutrophil ratio in sputum revealed that only
Mig was significantly correlated with the total of eosino-
phil ratio and neutrophil ratio (R = 0.40, P = 0.035) in pa-
tients with asthma.
Mig was significantly negatively correlated with %
FEV1 in patients with asthma (Fig. 4). IL-8 was also
negatively correlated with % FEV1 in patients with
asthma (R = −0.47, P = 0.002). The adjusted partial
correlation analysis revealed that Mig and IL-8 were
significantly negatively correlated with % FEV1 (Mig,
R = −0.34, P = 0.039; IL-8, R = −0.47, P = 0.003) in patients
with asthma. These negative correlations between them
were detected in all subjects with the adjusted partial









Subjects, n (%) 9 (23) 22 (56) 8 (21) 12
Eos dominant/Neu dominant, n (%) N. A. 19/3 (86/14) N. A. N. A.
Age, y 50 (20–71) 58 (30–71) 55 (22–72) 47 (30–57) N. S.
Male/female, n (Male, %) 3 (33)/6 9 (41)/13 4 (50)/4 4 (33)/8 N. S.
BMI 24.5 (6.1) 21.8 (2.5) 21.9 (1.0) 22.1 (3.1) N. S.
Duration of asthma (y) 5.1 (5.6) 10.8 (9.7) 23.4 (20.5)† N. A. 0.01
Ex-smokers, n (%) 4 (44) 9 (41) 1 (12) 0 (0) 0.03
Non-severe/Severe, n (Severe, %) 6/1 (11) 14/8 (36) 6/2 (25) N. A. N. S.
Medication
ICS dose (μg/day) 900 (500–1150) 800 (400–1150) 800 (400–1200) N. A. N. S.
LABA, n (%) 6 (67) 12 (55) 7 (88) N. A. N. S.
LTRA/TP, n (%) 6 (67)/3 (33) 13 (59)/11 (50) 7 (88)/4 (50) N. A. N. S.
Oral corticosteroids, n (%) 0 (0) 4 (18) 1 (13) N. A. N. S.
Atopy, n (%) 5 (57) 14 (64) 6 (75) 5 (42) N. S.
Asthma control and health care use, past year
β-agonist use/day 0.00 (0.00–0.01) 0.00 (0.00–0.02) 0.00 (0.00–0.68) N. A. N. S.
Oral Corticosteroid bursts 1.0 (1.0–2.5) 1.0 (0.0–1.0) 1.0 (0.0–2.0) N. A. N. S.
FEV1, L/min 2.3 (0.6) 2.1 (0.9)‡ 2.0 (1.0)§ 3.2 (0.8) 0.05
FEV1, % predicted 89.7 (14.9) 81.3 (22.4)װ 72.9 (18.2)¶ 105.5 (14.6) 0.01
FeNO, ppb 18.5 (12.3–45.5) 34.5 (13.3–51.0) 53.2 (21.5–99.0) N.D. N. S.
Data are presented as means (SD) unless otherwise indicated. Nonparametric data are shown as medians (25 to 75 %). Age is shown as mean (minimum
to maximum)
ICS = inhalation corticosteroid (beclomethasone), where 1 μg beclomethasone = 1 μg budesonide = 0.5 μg fluticasone
*P values are calculated with the use of the Kruskal-Wallis test and the Mann–Whitney U test for nonparametric data, ANOVA for variables with a parametric
distribution, and Fisher’s exact test for comparison of proportions. Initial analyses with a significant difference are further explored by post hoc pairwise analyses
(Bonferroni correction)
LABA, Long acting β2-agonist; LTRA, Leukotriene receptor antagonist; Eos, eosinophil, Neu, neutrophil
vs. Paucigranulocytic, † p = 0.01
vs. Healthy, ‡ p = 0.006; § p = 0.02; װ p = 0.004; ¶ p = 0.002
N. A.; not applicable. N.D.: not done
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Fig. 2 Sputum CXCR3 ligands and IL-8 in asthmatic patients classified by the sputum granulocyte ratio. The comparison of sputum CXCR3 ligands
and IL-8 among the 3 granulocytic subtypes and healthy subjects is shown in a IP-10, b Mig, c I-TAC and d IL-8. Each closed dot represents a
different subject. Boxes represent the 25th and 75th percentiles, the central line represents the median, and solid circles represent outliers. Error
bars indicate SDs. The comparison of CXCR3 ligands and IL-8 was analyzed using the Kruskal-Wallis test and the Mann–Whitney U test. Initial
analyses with a significant difference were further explored by post hoc pairwise analyses (Bonferroni correction). * v. s. Healthy, p < 0.0001; † v. s.
Eos or Neu, p = 0.04; ‡ v. s. Healthy, p = 0.04; § v. s. Pauci, p = 0.008; װ v. s. Healthy, p = 0.05; ¶ v. s. Healthy, p = 0.002; # v. s. Pauci, p = 0.05. Pauci,
Paucigranulocytic subtype; Eos or Neu, Eosinophil-dominant or Neutrophil-dominant subtype; Mixed, Mixed subtype
Table 3 Sputum cell characteristics, CXC3R ligands, and IL-8 stratified by subjects’ sputum eosinophil and neutrophil percentages
Paucigranulocytic Eosinophil-predominant
or Neutrophil-predominant
Mixed granulocytic Healthy subjects Overall
P value*
Subjects, n 9 22 (Eos/Neu, 19/3 ) 8 12
Cell population in sputum
% Squamous 30.5 (14.1) 18.5 (11.8) 12.2 (8.0) †, ‡ 30.4 (11.3) 0.002
% Mac 40.2 (12.1) †, § 28.9 (13.1) 15.5 (8.0) 19.6 (19.7) 0.002
% Lym 4.7 (4.2) 9.7 (6.3) 4.1 (2.6) 6.3 (7.7) N. S.
% Neu 23.7 (9.7) 30.4 (17.6) 57.1 (10.7) װ, ¶, # 32.6 (26.9) 0.003
% Eos 1.0 (0.6) 13.9 (14.5) ††, ‡‡ 10.9 (11.5) 0.5 (1.0) 0.002
% Eos + % Neu 24.6 (10.2) 45.1 (19.0) †, ‡ 68.1 (10.5)§§, װװ , ¶¶ 21.6 (5.5) <0.0001
CXC chemokine in sputum
IP-10 (pg/mL) 31.2 (31.2–242.1) 31.2 (31.2–156.6) 221.5 (92.7–411.6) §§,¶¶ 31.2 (31.2–31.2) 0.002
Mig (pg/mL) 588.1 (105.1–902.6) ## 763.3 (62.5–1916.0) ## 1938.1 (1121.1–2757.7) §§, ††† 62.5 (62.5–62.5) <0.0001
I-TAC (pg/mL) 7.8 (7.8–26.6) 7.8 (7.8–16.2) 7.8 (7.8–244.3) 7.8 (7.8–7.8) N. S.





(3.9, 1373.5–28075.2) §§§, װװװ
622.0 (2.9, 276.3–1709.6) 0.04
Data are presented as means (SD) unless otherwise indicated. Nonparametric data are shown as medians (25 to75 %)
*P values are calculated with the Kruskal-Wallis test and the Mann–Whitney U test for nonparametric data and ANOVA for variables with a parametric distribution.
Initial analyses with a significant difference are further explored by post hoc pairwise analyses (Bonferroni correction). Mac, Macrophages; Lym, Lymphocytes; Eos,
eosinophils; Neu, neutrophils
v. s. Healthy,† p = 0.01; װ p = 0.03; †† p = 0.006; §§ p < 0.0001; ## p = 0.04; ‡‡‡ p = 0.05; §§§ p = 0.002
v. s. Pauci, ‡ p = 0.01; ¶ p = 0.003; ‡‡ p = 0.02; װװ p < 0.0001; ††† p = 0.008; װװװ p = 0.05
v. s. Eosinophil-predominant or Neutrophil-predominant, # p = 0.006; ¶¶ p = 0.04
v. s. Mixed, § p = 0.005
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correlation analysis (Mig, R = −0.40, P = 0.005; IL-8,
R = −0.62, P < 0.0001). Neither in patients with
asthma nor all subjects, IP-10 and I-TAC were asso-
ciated with pulmonary function.
Discussion
This study showed that sputum IP-10 and Mig, members
of the CXCR3 ligands family, and IL-8 were higher in
asthma patients than in healthy subjects. Additionally,
according to the classification based on the proportion of
inflammatory granulocytes in sputum, IP-10, Mig and IL-
8 in sputum were higher in the mixed granulocyte subtype
than in healthy subjects. Elevations of Mig and IL-8 were
specifically intensified in the mixed granulocyte subtype
compared with the other granulocytic distribution asthma
subtypes. Nevertheless, the differences in CXC chemo-
kines between the severities of asthma were marginal.
These results suggest that CXC chemokines are more
relevant to express the characteristics of asthma endotypes
based on the proportion of sputum inflammatory granulo-
cytes than asthma phenotypes based on the clinical sever-
ities of asthma. Furthermore, three CXCR3 ligands were
associated with the total eosinophil and neutrophil ratio in
patients with asthma. Mig was also associated with pul-
monary function in patients with asthma. Consequently,
CXCR3 ligands may be involved in accumulated inflam-
matory granulocytes in the airways, and Mig may be in-
volved in the progression of the pathophysiology in the
airway in asthma. CXCR3 ligands might serve as a rele-
vant marker of the mixed granulocyte asthma subtype.
Viral infection- or allergen-triggered exacerbation of
allergic airway inflammation has been shown to increase
IP-10 in serum or BAL [35, 36]. The present findings
demonstrated the new information that IP-10 and Mig
were similarly elevated in sputum even in stable asthma
patients. CXCR3 is not exclusive to Th1 cells although
engagement of CXCR3 in Th1-type lymphocytes has
been the subject of particular interest. When activated,
Th2 cells express low levels of CXCR3 [46] and they
seem to be selectively recruited to the airways in re-
sponse to CXCR3 ligands [47, 48]. Chronic asthmatic
patients with high expressions of IL-27 mRNA on BAL
































































































































R = 0.48, P = 0.006 
R = 0.48, P = 0.002 R = 0.34, P = 0.034 
R = 0.36, P = 0.025 
Fig. 3 Correlations between CXCR3 ligands or IL-8, and total sputum eosinophil and neutrophil percentages in asthmatic patients. Associations
between data were determined using Pearson correlation coefficients. Correlations between combination of eosinophil percentage and neutrophil




















R = -0.40, P = 0.01
Fig. 4 Correlations between sputum CXCR3 ligands, and FEV1 %
predicted in asthmatic patients. Associations between data were
determined using Pearson correlation coefficients. Correlations
between Mig in sputum and FEV1 % predicted is shown
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be interpreted as evidence of high Th1 and high Th2 im-
munity, showed increased Mig mRNA expression on
epithelial cells [49]. Diverse environmental factors that
promote the Th1 immune axis, such as a workplace
agent [50], atypical bacteria [51], or fungi [52], may help
continuous production of CXCR3 ligands, since they are
produced by residual cells and leukocytes in response to
toll-like receptors or interferons [53]. The production of
CXCR3 ligands has been known to be induced by inter-
ferons. Therefore, IP-10 and Mig are likely involved in
the pathogenesis of chronic asthma.
In this study, sputum IP-10 and Mig levels in asthma
differed among the 3 granulocytic subtypes while not
between the clinical asthma severities. Additionally,
CXCR3 ligands were positively related to the total pro-
portion of eosinophils and neutrophils in asthma. These
results suggests that sputum CXCR3 ligand levels in
asthma seemed to represent the asthma phenotype
based on the ratios of granulocytes in sputum, rather
than the clinical asthma severity. Several studies showed
similar results. Eosinophilic asthma or asthma naïve to cor-
ticosteroids has higher expressions of eotaxin mRNA and
proteins in bronchial tissue or sputum cells [27, 28, 54].
Neutrophilic asthma has increased IL-8 in sputum [24, 25].
The SARP group’s report showed that brain-derived neuro-
trophic factor, IL-1β, and macrophage inflammatory protein
3a/CCL20 in sputum increased in asthmatic patients with
sputum containing ≥40 % neutrophils and tended to be
higher in those who with ≥40 % neutrophils and ≥2 % eo-
sinophils [21]. Considering these evidences, there were
some chemokines engaged in specific granulocyte recruit-
ment to the airway, leading to eosinophil or neutrophil-
predominant asthma.
Mig appeared to exert more specific roles than the
other CXCR3 ligands in the mixed granulocyte subtype
in the present study. Mig was markedly increased in the
mixed granulocyte subtype compared with the other
subtypes, whereas IP-10 was moderately elevated. Fur-
thermore, the partial correlation analysis adjusted with
age, eosinophils and neutrophils, revealed that only the
association between Mig and elevations of both granulo-
cytes was preserved in asthmatic patients. Mig was also
associated with deterioration of % FEV1 in asthmatic pa-
tients. These findings support the findings in the study
reported by Xie et al. They found that Mig-expressing
epithelial cells increased in asthmatic patients with high
expressions of Th1-type cytokine mRNA on BAL cells
and of Th2-type chemokine mRNA on epithelial cells, and
that those patients had the lowest % FEV1 among the
other asthma subtypes including Th1 cytokine high ex-
pression/Th2 chemokine low expression subtype, Th1
low/Th2 high, or Th1 low/ Th2 low [49]. Therefore, Mig
may represent the pathophysiologic features of the mixed
granulocyte subtype (high Th1 and high Th2 response).
The elevations of IP-10, Mig, and IL-8 in the mixed
granulocyte subtype would be attributed to the predom-
inant granulocyte of the two elevated granulocytes. Neu-
trophils were relatively predominant in the mixed
granulocyte subtype in the present study. Recent studies
have shown the expression of CXCR3 on neutrophils
from patients with chronic lung disease, but not in
healthy control subjects [45]. CXCR3 was highly
expressed in inflamed neutrophils in BAL obtained from
influenza virus-infected mice, and a reduction of neutro-
phils in BAL was reported in CXCR3 or IP-10 knockout
mice with viral- or acid-induced acute respiratory dis-
tress syndrome [34]. Therefore, IP-10 and Mig may pro-
mote neutrophil accumulation in the airways. Likewise,
the increase of eosinophils in sputum may affect this
phenomenon. In vitro, our previous study showed that
IP-10 and Mig enhanced adhesiveness of eosinophils to
ICAM-1 [55], which may be associated with elevations
of IP-10 and Mig in the mixed granulocyte subtype.
In the present study, asthma was divided into 3 pheno-
types based on the predominant granulocyte in sputum.
This kind of classification is generally considered clinic-
ally meaningful. This could lead to distinguishing fea-
tures from the mixed granulocyte phenotype. Severe
asthma is often characterized as airway inflammatory
disease combined with elevated eosinophils and neutro-
phils [5, 6, 8, 13, 16, 21–23, 43]. The recent SARP study
established this by showing that the rate of the mixed
granulocyte phenotype was higher in severe asthma
(45 %) [21]. The other analysis of a large number of sub-
jects from the SARP study also showed that the mixed
granulocyte phenotype had the poorest lung function
and poor asthma control [23]. The present findings sup-
port the previous evidence. In the present study, the
mixed granulocyte phenotype and the eosinophil or
neutrophil-predominant subtype accounted for more
than one quarter of severe asthma cases, and lung func-
tion in patients of this phenotype tended to be worse
than that with the paucigranulocytic subtype. Airway in-
flammation in asthma is originally composed of the
broad spectrum of diverse inflammatory cells. Many pa-
tients with asthma seem to exist at an intermediate stage
between the paucigranulocyte phenotype and the other
distinct granulocytic phenotypes. Taken together, this
pathological entity may express the characteristics of
asthma in real world practice.
There are some limitations in this study. First, this was
a small scale study. This may affect the results in terms
of the values of chemokines based on disease severity.
Second, CXC chemokines were not evaluated by dividing
asthma into the eosinophilic-predominant phenotype
and the neutrophilic-predominant phenotype. To further
interpret the present findings, further study may be
needed. Third, this is a cross sectional study design.
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Conclusion
This study showed that IP-10 and Mig as well as IL-8
elevated in an asthma phenotype with increase of eosino-
phils combined with neutrophils in airway. These CXCR3
ligands were also positively correlated with the total ratio
of granulocytes in sputum, which seems relevant to fixed
airway obstruction. Mig was also associated with the
decline of pulmonary function. Consequently, CXCR3
ligands, especially Mig, may be implicated in the combin-
ation of Th2-type and non-Th2-type bronchial inflamma-
tion in asthma.
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